Table 1.
Comparison | Quality of direct evidence | Quality of indirect evidence | Quality of network meta-analysis evidence |
Se vs placebo | Low*† | Low*‡ | Low*† |
Se salt vs placebo | Low*† | Low*‡ | Low*† |
Se+VC vs placebo | Moderate* | Low*‡ | Moderate* |
Se+VE vs placebo | Very low*†§ | Low*‡ | Low*‡ |
Se yeast vs placebo | Moderate* | Low*‡ | Moderate* |
VC vs placebo | Moderate* | Low*‡ | Moderate* |
Se salt vs Se | – | Very low*§¶ | Very low*§¶ |
Se+VC vs Se | Moderate* | Low*§ | Moderate* |
Se+VE vs Se | – | Very low*§¶ | Very low*§¶ |
Se yeast vs Se | Moderate* | Very low*§¶ | Moderate* |
VC vs Se | Moderate* | Low*¶ | Moderate* |
Se+VC vs Se salt | Low*‡ | Low*¶ | Low*¶ |
Se+VE vs Se salt | – | Very low*§¶ | Very low*§¶ |
Se yeast vs Se salt | – | Very low*§¶ | Very low*§¶ |
VC vs Se salt | Low*§ | Very low*§¶ | Low*,¶ |
Se+VE vs Se+VC | – | Very low*§¶ | Very low*§¶ |
Se yeast vs Se+VC | – | Very low*§¶ | Very low*§¶ |
VC vs Se+VC | Moderate* | Very low*§¶ | Moderate* |
Se yeast vs Se+VE | – | Very low*§¶ | Very low*§¶ |
VC vs Se+VE | – | Very low*§¶ | Very low*§¶ |
VC vs Se yeast | – | Very low*§¶ | Very low*§¶ |
*Limitations (risk of bias).
†Inconsistency.
‡Inconsistency for indirect evidence: prediction intervals for treatment effect include effects that would have different interpretations.
¶Indirectness: no convincing evidence for the plausibility of the transitivity assumption.
§Imprecision.
Se, sodium selenite; Se salt, selenium salt; Se+VC, the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E; Se yeast, selenium enriched yeast; VC, vitamin C.